N-(3-hydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)acetamide | 109093-42-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: N-(3-hydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)acetamide
• 英文别名: 6-acetamino-3-hydroxyflavone；6-acetamidoflavonol；N-(3-hydroxy-4-oxo-2-phenyl-chromen-6-yl)acetamide；N-(3-hydroxy-4-oxo-2-phenylchromen-6-yl)acetamide
• CAS: 109093-42-7
• 化学式: C₁₇H₁₃NO₄
• 分子量: 295.295
• InChiKey: PWIGEZNGVPAEHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-hydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)acetamide 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以100%的产率得到6-氨基-3-羟基-2-苯基-4H-苯并吡喃-4-酮
  参考文献：
  名称：

  新乙酰氨基和氨基黄酮衍生物的 1H 和 13C NMR 信号的合成和完整分配

  摘要：

  已使用包括 COSY、HMQC 和 HMBC 实验在内的一维和二维 NMR 技术对 9 种乙酰氨基查耳酮、18 种乙酰氨基黄酮、18 种氨基黄酮、9 种乙酰氨基黄酮醇和 9 种氨基黄酮醇进行了完整的 1H 和 13C NMR 归属。版权所有 © 2010 John Wiley & Sons, Ltd.

  DOI：

  10.1002/mrc.2638
• 作为产物：
  描述：

  4'-甲氧基乙酰苯胺 在 aluminum (III) chloride 、 lithium hydroxide monohydrate 、 双氧水 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 6.37h， 生成 N-(3-hydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)acetamide
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES
  [FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE

  摘要：

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。

  公开号：

  WO2016083490A1

文献信息

• Synthesis and Anti-cancer Activity of Novel Thiazolidinone Analogs of 6-Aminoflavone
  作者：Sudheer Moorkoth

  DOI：10.1248/cpb.c15-00454

  日期：——

  Novel heterocyclic analogs were synthesized by combining a flavone nucleus and thiazolidinone ring in an effort to potentiate the existing anti-cancer activity of flavone. The syntheses of 6-aminoflavone, 6-amino-3-methoxyflavone, 6-amino-3-methoxy-3′,4′-dimethxyflavone and their corresponding thiazolidinone analogs were performed. Fifteen novel analogs were synthesized and evaluated for their anti-cancer activity using cell-based assay techniques and in vivo testing. As expected, the analogs improved cytotoxicity and were shown to increase the life span of cancer-bearing mice. Cytotoxicity was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays in HeLa, MDA-MB-435, and Vero cell lines. In vivo evaluation of anti-cancer activity performed in albino mice bearing Dalton’s ascites carcinoma showed that the new analogs enhanced life span and prevented increases in body weight owing to tumor volumes. Moreover, cell-cycle analysis and Hoechst staining analysis proved the apoptotic potential of these analogs. Preliminary pharmacokinetic evaluation was carried out on the synthesized compounds to determine the lipophilicity and pKa. Lipophilicity was determined using high-performance liquid chromatography and the results showed a direct correlation between the observed anti-cancer activity and log P value, while pKa values indicated the ionizing range which is a prediction tool for solubility and permeability.

  通过将黄酮核与噻唑烷二酮环结合，合成了一系列新型杂环类似物，旨在增强黄酮已知的抗癌活性。合成了6-氨基黄酮、6-氨基-3-甲氧基黄酮、6-氨基-3-甲氧基-3′，4′-二甲氧基黄酮及其相应的噻唑烷二酮类似物。合成了十五种新型类似物，并通过基于细胞的检测技术和小鼠体内的癌症检测试验，评估了它们的抗癌活性。如预期的，这些类似物提高了细胞毒性，并显示出能延长携癌小鼠的寿命。细胞毒性评估使用了3-(4,5-二甲基噻唑-2-基)-2, 5-二苯基四唑溴盐（MTT）法在HeLa，MDA-MB-435和Vero细胞系上进行。在患有Dalton腹水癌的白色小鼠中的体内抗癌活性评价表明，这些新类似物延长了生命周期并阻止了肿瘤体积导致的体重增加。此外，细胞周期分析和Hoechst染色分析证明了这些类似物的凋亡潜力。对合成的化合物进行了初步的药代动力学评价，以确定其亲脂性和pKa。通过高效液相色谱法确定亲脂性，结果显示出观察到的抗癌活性和log P值之间的直接关联，而pKa值指示了电离范围，这是预测溶解度和渗透性的工具。
• Flavonols
  申请人：The University of Melbourne

  公开号：US07863323B1

  公开（公告）日：2011-01-04

  A compound of the formula (I): wherein R is selected from the group consisting of H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl and acyl, each of which may be optionally substituted; R1 is an organic moiety that is capable of being converted into a charged group; each X and Y is independently selected from the group consisting of H, halogen, —CN, —NO2, —CF3, —OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, arylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, phenoxy, benzyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, —COOH, —COR2, —COOR2, —CONHR2, —NHCOR2, —NHCOOR2, —NHCONHR2, C(═NOH)R2, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR2 and acyl, each of which may be optionally substituted; each R2 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, and acyl, each of which may be optionally substituted; m is an integer selected from the group consisting of 0, 1, 2, 3, 4 and 5; p is an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt or prodrug thereof.

  公式（I）的化合物：其中R从H、烷基、烯基、炔基、杂原子烷基、环烷基、杂环烷基、芳基、杂芳基和酰基组成的群中选择，每个都可以选择性地被取代；R1是一个有能力转化为带电基团的有机基团；每个X和Y分别从H、卤素、—CN、—NO2、—CF3、—OCF3、烷基、烯基、炔基、卤代烷基、卤代烯基、杂原子烷基、环烷基、环烯基、杂环烷基、杂环烯基、芳基、杂芳基、环烷基烷基、杂环烷基烷基、芳基烷基、杂芳基烷基、芳基烯基、环烷基杂原子烷基、芳基杂原子烷基、杂环烷基杂原子烷基、杂芳基杂原子烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧基芳基、烯基氧基、炔基氧基、环烷氧基、杂环烷氧基、芳氧基、杂芳氧基、芳基烷氧基、苯氧基、苄氧基、氨基、烷基氨基、氨基烷基、酰氨基、芳基氨基、磺酰氨基、亚砜氨基、—COOH、—COR2、—COOR2、—CONHR2、—NHCOR2、—NHCOOR2、—NHCONHR2、C(═NOH)R2、烷氧羰基、烷基氨基羰基、磺酰基、烷基磺酰基、烷基亚砜基、芳基磺酰基、芳基亚砜基、氨基磺酰基、SR2和酰基组成的群中选择，每个都可以选择性地被取代；每个R2从H、烷基、烯基、炔基、卤代烷基、杂原子烷基、环烷基、杂环烷基、芳基、杂芳基、环烷基烷基、杂环烷基烷基、芳基烷基、杂芳基烷基和酰基组成的群中选择，每个都可以选择性地被取代；m是从0、1、2、3、4和5中选择的整数；p是从0、1、2和3中选择的整数；或其药用盐或前药。
• Anti-HIV and antiplasmodial activity of original flavonoid derivatives
  作者：Gilles Casano、Aurélien Dumètre、Christophe Pannecouque、Sébastien Hutter、Nadine Azas、Maxime Robin

  DOI：10.1016/j.bmc.2010.06.067

  日期：2010.8

  In our search for potent anti-HIV and antiplasmodial agents, novel series of flavonoid derivatives and their chalcone intermediates were synthesized and evaluated for inhibition of HIV multiplication and antiproliferative activity on Plasmodium falciparum parasites. Chalcones exhibited a more selective antiplasmodial activity than flavonoids. Methoxyflavone 7e was the only one compound active in both P. falciparum and HIV-1 whereas aminomethoxyflavones showed activity against HIV-2. Para substitution on the B ring seemed to increase HIV-2 potency. (C) 2010 Elsevier Ltd. All rights reserved.
• US7863323B1
  申请人：——

  公开号：US7863323B1

  公开（公告）日：2011-01-04
• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。